CRISPR Therapeutics Down 5.3% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics reported Q2 2025 loss of $2.40 per share, wider than the year-ago period's loss of $1.49, due to a $96.3 million payment for a strategic collaboration agreement. Total revenues were $0.89 million, missing the Zacks Consensus Estimate of $6.6 million. R&D expenses declined 13% YoY, while general and administrative expenses fell 3% YoY. The company had cash, cash equivalents, and marketable securities worth $1.72 billion as of June 30, 2025. Estimates have been trending upward for the stock, with a Zacks Rank #3 (Hold).

Title: ARK ETF Bolsters Holdings in CRISPR and Bitmine, Reflects Growing Interest in Gene Editing

ARK Invest's ETFs, managed by Cathie Wood, have seen significant activity in recent trading sessions, particularly in the tech and biotech sectors. On Wednesday, August 27th, 2025, ARKK, ARKW, and ARKF ETFs made notable investments and divestments, providing insights into the fund's strategic focus.

ARK increased its stake in Bitmine Immersion Technologies Inc (OTC:BMNR) by acquiring 339,113 shares across its ETFs, with a total value of approximately $16.94 million. This substantial investment underscores ARK's belief in the potential of Bitmine's immersion technologies [1].

ARK also continued to bolster its position in CRISPR Therapeutics AG (NASDAQ:CRSP), purchasing an additional 124,275 shares through its ARKK ETF, amounting to a $6.82 million investment. This move follows a series of consistent purchases in CRISPR, indicating a bullish stance on the gene-editing company's future [1].

On the selling side, ARK divested from DraftKings Inc (NASDAQ:DKNG), offloading 266,052 shares across the same three ETFs for a total value of nearly $12.69 million. This sale marks a continuation of ARK’s reducing position in the online sports betting company [1].

ARK also increased its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by buying 185,200 shares through ARKK, with a total value of $2.10 million. This follows a series of purchases in Intellia, underscoring ARK’s confidence in the biotechnology firm specializing in genome editing [1].

Conversely, ARK sold 85,278 shares of Roku Inc (NASDAQ:ROKU) from its ARKK ETF, valued at approximately $8.15 million. The sale continues a trend of ARK reducing its exposure to the streaming device company [1].

Investors and market watchers tracking ARK’s movements will note the ETF’s strategic shifts, with a clear focus on innovative and disruptive companies in the technology and biotech industries. These daily trade reports provide insight into Cathie Wood’s investment strategy, offering a glimpse into where ARK sees potential growth and where it is choosing to cut back.

References

[1] https://www.investing.com/news/company-news/cathie-woods-ark-etf-bolsters-bitmine-and-crispr-stock-holdings-93CH-4213655